

Infliximab and immunomodulators reduce immunogenicity of a single-dose of SARS-CoV-2 vaccines

<b>Title</b>	<b>Infliximab is associated with attenuated immunogenicity to BNT162b2 and ChAdOx1 nCoV-19 SARS-CoV-2 vaccines</b>
<b>Authors</b>	<p>Nicholas A Kennedy, PhD<sup>1,2*</sup>, Simeng Lin, MBChB<sup>1,2*</sup>, James R Goodhand, MBBS<sup>1,2*</sup>, Neil Chanchlani, MBChB<sup>1,2</sup>, Ben Hamilton MBBS<sup>1,2</sup>, Claire Bewshea, MSc<sup>2</sup>, Rachel Nice, MSc<sup>2,3</sup>, Desmond Chee, MBBS<sup>1,2</sup>, JR Fraser Cummings, DPhil<sup>4</sup>, Aileen Fraser, MSc<sup>5</sup>, Peter M Irving, MD<sup>6,7</sup>, Nikolaos Kamperidis, MD<sup>8</sup>, Klaartje B Kok, PhD<sup>9,10</sup>, Christopher A Lamb, PhD<sup>11,12</sup>, Jonathan Macdonald, BM<sup>13,14</sup>, Shameer J Mehta, MD<sup>15</sup>, Richard CG Pollok, PhD<sup>16,17</sup>, Tim Raine, PhD<sup>18</sup>, Philip J Smith, MBBS<sup>19</sup>, Ajay M Verma, MD<sup>20</sup>, Timothy J McDonald, PhD<sup>2,3</sup>, Shaji Sebastian, MD<sup>21, 22</sup>, Charlie W Lees, PhD<sup>23,24</sup>, Nick Powell, PhD<sup>25,26*</sup>, Tariq Ahmad, DPhil<sup>1,2*</sup>, Contributors to the CLARITY IBD study</p> <p>*denotes equal contribution</p>
<b>Affiliations</b>	<p><sup>1</sup> Department of Gastroenterology, Royal Devon and Exeter NHS Foundation Trust, Exeter, UK</p> <p><sup>2</sup> Exeter Inflammatory Bowel Disease and Pharmacogenetics Research Group, University of Exeter, UK</p> <p><sup>3</sup> Department of Biochemistry, Exeter Clinical Laboratory International, Royal Devon and Exeter NHS Foundation Trust, Exeter, UK</p> <p><sup>4</sup> Department of Gastroenterology, University Hospital Southampton NHS Foundation Trust, Southampton, UK</p> <p><sup>5</sup> Department of Gastroenterology, University Hospitals Bristol NHS Foundation Trust, Bristol, UK</p> <p><sup>6</sup> Department of Gastroenterology, Guy's and St Thomas' NHS</p>

## Infliximab and immunomodulators reduce immunogenicity of a single-dose of SARS-CoV-2 vaccines

	<p>Foundation Trust, London, UK</p> <p><sup>7</sup>School of Immunology &amp; Microbial Sciences, King's College London, London, UK</p> <p><sup>8</sup>Department of Gastroenterology, St Marks Hospital and Academic Institute, London, UK</p> <p><sup>9</sup>Centre for Immunobiology, Blizard Institute, Barts and the London School of Medicine, Queen Mary University of London, London, UK</p> <p><sup>10</sup>Department of Gastroenterology, Royal London Hospital, Barts Health NHS Trust, London, UK</p> <p><sup>11</sup> Department of Gastroenterology, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK</p> <p><sup>12</sup> Translational &amp; Clinical Research Institute, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, UK</p> <p><sup>13</sup> Department of Gastroenterology, Queen Elizabeth University Hospital, NHS Greater Glasgow and Clyde, Glasgow, UK</p> <p><sup>14</sup> School of Medicine, Dentistry and Nursing, University of Glasgow, Glasgow, UK</p> <p><sup>15</sup> Department of Gastroenterology, University College London Hospitals NHS Foundation Trust, London, UK</p> <p><sup>16</sup> Department of Gastroenterology, St George's University Hospital NHS Foundation Trust, London, UK</p> <p><sup>17</sup> Institute for Infection &amp; Immunity, St George's, University of London, London, UK</p> <p><sup>18</sup> Department of Gastroenterology, Addenbrooke's Hospital, Cambridge</p>
--	--

Infliximab and immunomodulators reduce immunogenicity of a single-dose of SARS-CoV-2 vaccines

	<p>University Hospitals NHS Foundation Trust, Cambridge, UK</p> <p><sup>19</sup> Department of Gastroenterology, Royal Liverpool Hospital, Liverpool University Hospitals NHS Foundation Trust, Liverpool, UK</p> <p><sup>20</sup> Department of Gastroenterology, Kettering General Hospital, Kettering, UK</p> <p><sup>21</sup> IBD Unit, Department of Gastroenterology, Hull University Teaching Hospitals NHS Trust, Hull, UK</p> <p><sup>22</sup> Hull York Medical School, University of Hull, Hull, UK</p> <p><sup>23</sup> Department of Gastroenterology, Western General Hospital, NHS Lothian, Edinburgh, UK</p> <p><sup>24</sup> Institute of Genetic and Molecular Medicine, University of Edinburgh, Edinburgh, UK; Department of Gastroenterology, Western General Hospital, Edinburgh, UK</p> <p><sup>25</sup> Department of Gastroenterology, Imperial College Healthcare NHS Trust, London, UK</p> <p><sup>26</sup> Department of Metabolism, Digestion and Reproduction, Imperial College London, London, UK</p>
<b>Address for correspondence</b>	<p>Prof Tariq Ahmad, Exeter Inflammatory Bowel Disease and Pharmacogenetics Research Group, RILD building, Barrack Road, Exeter. EX2 5DW, UK tariq.ahmad1@nhs.net</p>
<b>Key words</b>	<p>SARS-CoV-2, immune-mediated inflammatory diseases, inflammatory bowel disease, anti-TNF therapy, infliximab, vedolizumab, immunosuppressant, vaccine, ChAdOx1 nCoV-19, BNT162b2, CLARITY</p>
<b>Running title</b>	<p>Infliximab and immunomodulators reduce immunogenicity of a single- dose of SARS-CoV-2 vaccines.</p>
<b>Word count</b>	<p>2939</p>

## Infliximab and immunomodulators reduce immunogenicity of a single-dose of SARS-CoV-2 vaccines

### 2 **Research in context**

#### 3 ***Evidence before this study***

4 Faced with further surges of SARS-CoV-2 infection, a growing number of countries, including the UK,  
5 have opted to delay second vaccine doses for all people. This strategy trades maximal effectiveness  
6 against a lower level of protective immunity across more of the at-risk population.

7 We have previously shown that seroprevalence, seroconversion in PCR-confirmed cases, and the  
8 magnitude of anti-SARS-CoV-2 antibodies following SARS-CoV-2 infection are reduced in infliximab-  
9 compared with vedolizumab-treated patients. Whether single-doses of vaccines are effective in  
10 patients treated with anti-TNF therapies is unknown.

11 We searched PubMed from 25 November 2019 to 23 March 2021 with the terms “anti-tumour  
12 necrosis factor” or “anti-integrin” or “infliximab” or “adalimumab” or “vedolizumab” or “biological  
13 therapy” or “biologic therapy” AND “SARS-CoV-2” or “coronavirus” or “COVID-19” or AND  
14 “seroprevalence” or “seroconversion” or “antibody” or “antibody response” or “magnitude” or  
15 “immunogenicity” AND “vaccine” or “vaccination” or “immunisation” or “immunization” or  
16 “ChAdOx1 nCoV-19” or “BNT162b2” or “mRNA-1273”, without restriction on language.

17 Serological responses to SARS-CoV-2 vaccines have been reported in registration trials and small  
18 observational cohorts of healthy volunteers. Two small studies, including one unpublished preprint,  
19 found that COVID-19 vaccine immunogenicity rates were lower in transplant recipients and patients  
20 with malignancy receiving immunosuppressive therapy, and fewer patients treated with potent  
21 immunosuppressants seroconverted than healthy controls. No studies have assessed the effect of  
22 anti-TNF therapy on immunogenicity following SARS-CoV-2 vaccination.

23

## Infliximab and immunomodulators reduce immunogenicity of a single-dose of SARS-CoV-2 vaccines

### 24 ***Added value of this study***

25 To test if anti-TNF drugs attenuate serological responses to primary SARS-CoV-2 vaccines, we  
26 analysed anti-SARS-CoV-2 spike (S) antibody concentrations and seroconversion rates in 1293  
27 patients with inflammatory bowel disease who received primary vaccinations with either the  
28 ChAdOx1 nCoV-19 or BNT162b2 vaccines. 865 were treated with the anti-TNF drug infliximab and  
29 outcomes were compared to a reference cohort of 428 patients treated with vedolizumab, a gut  
30 selective anti-integrin  $\alpha 4\beta 7$  monoclonal antibody that is not associated with impaired systemic  
31 immune responses.

32 Anti-SARS-CoV-2 antibody levels and rates of seroconversion were lower following primary  
33 vaccination with both the BNT162b2 and ChAdOx1 nCoV-19 vaccines in patients with IBD treated  
34 with infliximab compared to vedolizumab. Older age, immunomodulator use, Crohn's disease  
35 (versus ulcerative colitis or inflammatory bowel disease unclassified), and current smoking were  
36 associated with lower anti-SARS-CoV-2 antibody concentrations, irrespective of vaccine type. Non-  
37 white ethnicity was associated with higher anti-SARS-CoV-2 (S) antibody concentrations following  
38 primary vaccination with both vaccines. Antibody concentrations and seroconversion rates were  
39 higher in patients with past SARS-CoV-2 infection prior to a single-dose of either vaccine, and after 2  
40 doses of the BNT162b2 vaccine.

### 41 ***Implications of the available evidence***

42 Our findings have important implications for patients treated with anti-TNF therapy, particularly for  
43 those also treated with an immunomodulator. Poor antibody responses to a single-dose of vaccine  
44 exposes these patients to a potential increased risk of SARS-CoV-2 infection. However, higher rates  
45 of seroconversion in patients with two exposures to SARS-CoV-2 antigen, even in the presence of  
46 TNF blockade, suggest that all patients receiving these drugs should be prioritized for optimally

## Infliximab and immunomodulators reduce immunogenicity of a single-dose of SARS-CoV-2 vaccines

47    timed second doses. Until patients receive a second vaccine dose, they should consider that they are  
48    not protected from SARS-CoV-2 infection and continue to practice enhanced physical distancing and  
49    shielding if appropriate. Even after two antigen exposures, a small subset of patients failed to mount  
50    an antibody response. Antibody testing and adapted vaccine schedules should be considered to  
51    protect these at-risk patients.

## Infliximab and immunomodulators reduce immunogenicity of a single-dose of SARS-CoV-2 vaccines

### 52 **Abstract**

#### 53 *Background*

54 Delayed second-dose SARS-CoV-2 vaccination trades maximal effectiveness for a lower level of  
55 immunity across more of the population. We investigated whether patients with inflammatory  
56 bowel disease treated with infliximab have attenuated serological responses to a single-dose of a  
57 SARS-CoV-2 vaccine.

#### 58 *Methods*

59 Antibody responses and seroconversion rates in infliximab-treated patients (n=865) were compared  
60 to a cohort treated with vedolizumab (n=428), a gut-selective anti-integrin  $\alpha 4\beta 7$  monoclonal  
61 antibody. Our primary outcome was anti-SARS-CoV-2 spike (S) antibody concentrations 3-10 weeks  
62 after vaccination in patients without evidence of prior infection. Secondary outcomes were  
63 seroconversion rates, and antibody responses following past infection or a second dose of the  
64 BNT162b2 vaccine.

#### 65 *Findings*

66 Geometric mean [SD] anti-SARS-CoV-2 antibody concentrations were lower in patients treated with  
67 infliximab than vedolizumab, following BNT162b2 (6.0 U/mL [5.9] vs 28.8 U/mL [5.4]  $P < 0.0001$ ) and  
68 ChAdOx1 nCoV-19 (4.7 U/mL [4.9] vs 13.8 U/mL [5.9]  $P < 0.0001$ ) vaccines. In our multivariable  
69 models, antibody concentrations were lower in infliximab- compared to vedolizumab-treated  
70 patients who received the BNT162b2 (fold change [FC] 0.29 [95% CI 0.21, 0.40],  $p < 0.0001$ ) and  
71 ChAdOx1 nCoV-19 (FC 0.39 [95% CI 0.30, 0.51],  $p < 0.0001$ ) vaccines. In both models, age  $\geq 60$  years,  
72 immunomodulator use, Crohn's disease, and smoking were associated with lower, whilst non-white  
73 ethnicity was associated with higher, anti-SARS-CoV-2 antibody concentrations. Seroconversion  
74 rates after a single-dose of either vaccine were higher in patients with prior SARS-CoV-2 infection  
75 and after two doses of BNT162b2 vaccine.

## Infliximab and immunomodulators reduce immunogenicity of a single-dose of SARS-CoV-2 vaccines

### 76 *Interpretation*

77 Infliximab is associated with attenuated immunogenicity to a single-dose of the BNT162b2 and  
78 ChAdOx1 nCoV-19 SARS-CoV-2 vaccines. Vaccination after SARS-CoV-2 infection, or a second dose of  
79 vaccine, led to seroconversion in most patients. Delayed second dosing should be avoided in  
80 patients treated with infliximab.

81

### 82 *Funding*

83 Royal Devon and Exeter and Hull University Hospital Foundation NHS Trusts. Unrestricted  
84 educational grants: F. Hoffmann-La Roche AG (Switzerland), Biogen GmbH (Switzerland), Celltrion  
85 Healthcare (South Korea) and Galapagos NV (Belgium).



## Infliximab and immunomodulators reduce immunogenicity of a single-dose of SARS-CoV-2 vaccines

### 86 Introduction

87 Limited SARS-CoV-2 vaccine supplies and pressure on critical care services have forced governments  
88 to prioritise primary vaccination to vulnerable groups. In the United Kingdom, second vaccine doses  
89 have also been delayed, trading maximal effectiveness for a lower level of protective immunity  
90 across a greater proportion of the most at-risk population.<sup>1</sup> Consequently, more than half of the  
91 adult population have received a single-dose of either the RNA vaccine, BNT162b2 (Pfizer/BioNTech)  
92 or the adenovirus-vector vaccine, ChAdOx1 nCoV-19 (Oxford/AstraZeneca). Faced with further  
93 surges of SARS-CoV-2 infection, a growing number of other countries have also opted to delay  
94 second vaccine doses.<sup>2,3</sup>

95 The inflammatory bowel diseases (IBD), Crohn's disease and ulcerative colitis (UC) are chronic  
96 immune-mediated inflammatory diseases (IMIDs) that affect about 1% of the UK population.<sup>4,5</sup>  
97 Treatment typically requires immunosuppression with immunomodulators (azathioprine,  
98 mercaptopurine, and methotrexate) and/or biological therapies that target disease relevant  
99 cytokines or the immune cells that produce them. Anti-tumour necrosis factor (TNF) drugs, such as  
100 infliximab and adalimumab, are the most frequently prescribed biopharmaceuticals used in the  
101 treatment of IMIDs. These drugs impair immunogenicity following pneumococcal,<sup>6</sup> influenza,<sup>7</sup> and  
102 hepatitis B<sup>8</sup> vaccinations and increase the risk of serious infection, most notably with respiratory  
103 pathogens.<sup>9</sup> Conversely, vedolizumab, a gut-selective anti-integrin  $\alpha 4\beta 7$  monoclonal antibody is not  
104 associated with increased susceptibility to systemic infection or attenuated serological responses to  
105 vaccination.<sup>10</sup>

106 We have recently reported that seroprevalence, seroconversion in PCR-confirmed cases, and the  
107 magnitude of anti-SARS-CoV-2 antibodies following SARS-CoV-2 infection are reduced in infliximab-  
108 compared with vedolizumab-treated patients.<sup>11</sup> We hypothesised that, following at least a single-  
109 dose with BNT162b2 or ChAdOx1 nCoV-19 vaccine, serological responses would be similarly

## Infliximab and immunomodulators reduce immunogenicity of a single-dose of SARS-CoV-2 vaccines

110 impaired in patients treated with infliximab compared to vedolizumab arguing against delaying  
111 second doses in these patients.

112

113 We aimed to define, in patients with IBD who had received a COVID-19 vaccination, whether biologic  
114 class and concomitant use of an immunomodulator impact:

- 115 i) anti-SARS-CoV-2 spike (S) antibody levels
- 116 ii) rates of seroconversion
- 117 iii) antibody responses in patients who had previously been infected with SARS-CoV-2 or who  
118 had two doses of vaccine

119

## Infliximab and immunomodulators reduce immunogenicity of a single-dose of SARS-CoV-2 vaccines

### 120 **Methods**

#### 121 *Study design and participants*

122 impaCt of bioLogic therApy on saRs-cov-2 Infection and immuniTY (CLARITY) IBD is a UK wide,  
123 multicentre, prospective observational cohort study investigating the impact of infliximab and  
124 vedolizumab and/or concomitant immunomodulators (azathioprine, mercaptopurine, and  
125 methotrexate) on SARS-CoV-2 acquisition, illness, and immunity in patients with IBD.

126 Study methods have been described in detail previously.<sup>11</sup> In brief, consecutive patients were  
127 recruited at the time of attendance at infusion units from 92 National Health Service (NHS) hospitals  
128 across the UK between 22<sup>nd</sup> September 2020 and 23<sup>rd</sup> December 2020 (Supplementary pp 2 - 17).  
129 The eligibility criteria were age 5 years and over, a diagnosis of IBD, and current treatment with  
130 infliximab or vedolizumab for 6 weeks or more, with at least one dose of drug received in the  
131 previous 16 weeks. Patients were excluded if they had participated in a SARS-CoV-2 vaccine trial.

132 Follow-up visits were timed to coincide with biologic infusions and occurred approximately eight-  
133 weekly. Here, we report vaccine-induced antibody responses at first study visit after primary  
134 vaccination, and where possible, after two doses. Participants were eligible for inclusion in our  
135 vaccine immunogenicity analysis if they had had a SARS-CoV-2 antibody test within the first ten  
136 weeks after their primary vaccination with any of the available SARS-CoV-2 vaccines.

137 The Surrey Borders Research Ethics committee approved the study (REC reference: 20/HRA/3114) in  
138 September 2020. Patients were included after providing informed, written consent. The sponsor was  
139 the Royal Devon and Exeter NHS Foundation Trust. The protocol is available online at  
140 <https://www.clarityibd.org>. The study was registered with the ISRCTN registry, ISRCTN45176516.

## Infliximab and immunomodulators reduce immunogenicity of a single-dose of SARS-CoV-2 vaccines

### 141 *Procedures*

142 Variables recorded by participants were demographics (age, sex, ethnicity, comorbidities, height and  
143 weight, smoking status, and postcode), IBD disease activity (PRO2), SARS-CoV-2 symptoms aligned to  
144 the COVID-19 symptoms study (symptoms, previous testing, and hospital admissions for COVID-19),  
145 and vaccine uptake (type and date of primary vaccination). Study sites completed data relating to  
146 IBD history (age at diagnosis, disease duration, and phenotype according to the Montreal  
147 classifications, previous surgeries, and duration of current biologic and immunomodulator  
148 therapy).<sup>11</sup> We linked our data by NHS number or Community Health Index to Public Health England,  
149 Scotland, and Wales who archive dates and results of all SARS-CoV-2 PCR tests undertaken. Data  
150 were entered electronically into a purpose-designed REDCap database hosted at the Royal Devon  
151 and Exeter NHS Foundation Trust.<sup>12</sup> Participants without access to the internet or electronic device  
152 completed their questionnaires on paper case record forms that were subsequently entered by local  
153 research teams.

154 Laboratory analyses were performed at the Academic Department of Blood Sciences at the Royal  
155 Devon and Exeter NHS Foundation Trust. To determine antibody responses specific to vaccination  
156 we used the Roche Elecsys Anti-SARS-CoV-2 spike (S) immunoassay<sup>13</sup> alongside the nucleocapsid (N)  
157 immunoassay.<sup>14</sup> This double sandwich electrochemiluminescence immunoassay uses a recombinant  
158 protein of the receptor binding domain on the spike protein as an antigen for the determination of  
159 antibodies against SARS-CoV-2. Sample electrochemiluminescence signals are compared to an  
160 internal calibration curve and quantitative values are reported as units (U)/mL.

161 In-house assay validation experiments demonstrated:

162 i) The intra-assay and inter-assay coefficient of variation were 1.3% and 5.6%, respectively

## Infliximab and immunomodulators reduce immunogenicity of a single-dose of SARS-CoV-2 vaccines

163 ii) Anti-SARS-CoV-2 (S) antibodies were stable in uncentrifuged blood and serum at ambient  
164 temperature for up to seven days permitting postal transport

165 iii) No effect was observed on recovery of anti-SARS-CoV-2 (S) antibodies following four  
166 freeze/thaw cycles

167 iv) No analytical interference was observed for the detection of anti-SARS-CoV-2 (S) with  
168 infliximab or vedolizumab up to 10,000 mg/L and 60,000 mg/L, respectively, or with anti-  
169 drug antibodies to infliximab or vedolizumab up to 400 AU/mL and 38 AU/mL, respectively  
170 (data not shown).

171 At entry to CLARITY IBD and at follow-up visits, all patients were tested for previous SARS-CoV-2  
172 infection using the Roche Elecsys anti-SARS-CoV-2 (N) immunoassay. Because antibody responses  
173 are impaired following PCR-confirmed natural infection we set a threshold of 0.25 times the cut-off  
174 index (COI) at or above which patients were deemed to have had prior infection.<sup>11</sup> We defined a  
175 second threshold of 0.12 times the COI, below which patients were deemed to have no evidence of  
176 prior infection. Patients with a PCR test confirming SARS-CoV-2 infection at any time prior to  
177 vaccination were deemed to have evidence of past infection irrespective of any antibody test result.

### 178 *Outcomes*

179 Our primary outcome was anti-SARS-CoV-2 anti-spike (S) protein receptor-binding protein antibodies  
180 three to ten weeks after primary vaccination.

181 Secondary outcomes were:

182 (i) proportion of participants with seroconversion, defined by a threshold which has been  
183 associated with pseudoneutralisation in vitro.

184 (ii) antibody concentrations and seroconversion in patients with PCR or serological evidence  
185 of past SARS-CoV-2 infection at, or prior, to the post-vaccination serum sample.

186 (iii) antibody concentrations and seroconversion after two doses of vaccine.

## Infliximab and immunomodulators reduce immunogenicity of a single-dose of SARS-CoV-2 vaccines

187

### 188 *Statistical Analysis*

189 The sample size for CLARITY IBD was based on the number of participants required to demonstrate a  
190 difference in the impact of infliximab and vedolizumab on seroprevalence and seroconversion  
191 following SARS-CoV-2 infection, with an estimated background seroprevalence of 0.05. We  
192 calculated that a sample of 6970 patients would provide 80% power to detect differences in the  
193 seroprevalence of anti-SARS-CoV-2 antibodies in infliximab- compared with vedolizumab-treated  
194 patients, whilst controlling for immunomodulator status at the 0.05 significance level. We stored and  
195 then analysed all serum samples as soon as the Roche Elecsys anti-SARS-CoV-2 (S) immunoassay was  
196 established in our laboratory.

197 Statistical analyses were undertaken in R 4.0.4 (R Foundation for Statistical Computing, Vienna,  
198 Austria). All tests were two tailed and p-values <0.05 were considered significant. We included  
199 patients with missing clinical data in analyses for which they had data and have specified the  
200 denominator for each variable. Anti-S antibody concentrations are reported as geometric means and  
201 standard deviations. Other continuous data are reported as median and interquartile range, and  
202 discrete data as numbers and percentages, unless otherwise stated.

203 Univariable analyses, using t-tests of log-transformed anti-SARS-CoV-2 (S) antibody concentration  
204 and Spearman's rank correlation coefficients, were used to identify demographic, disease, vaccine,  
205 and treatment-related factors associated with the concentration of anti-SARS-CoV-2 (S) antibodies.  
206 To test our primary outcome, we used multivariable linear regression models to identify factors  
207 independently associated with log anti-SARS-CoV-2 (S) levels. A priori, we included age, ethnicity,  
208 biologic medication, and immunomodulator use. No stepwise regression was performed. Results are  
209 presented after exponentiation, so that the coefficients of the model correspond to the fold change  
210 associated with each binary covariate. For age, a cut-off was chosen based on graphical inspection of

## Infliximab and immunomodulators reduce immunogenicity of a single-dose of SARS-CoV-2 vaccines

211 the relationship between age and anti-SARS-CoV-2 (S) antibody concentrations. We also report the  
212 proportions of patients who seroconverted following vaccination. Seroconversion was defined by an  
213 optimized cut-off of 15 U/mL, with a positive predictive value of 99.1%, based on the correlation  
214 between receptor-binding domain antibodies and the cPass SARS-CoV-2 surrogate virus  
215 neutralisation test (internal data, Roche Diagnostics GmbH, Germany).<sup>15,16</sup> We conducted sensitivity  
216 analyses to compare antibody responses stratified by participants with serological or PCR evidence  
217 of SARS-CoV-2 infection at any time prior to vaccination and in those who had received 2 doses of  
218 vaccine.

### 219 *Role of the funding source*

220 CLARITY IBD is an investigator-led, UK National Institute for Health Research COVID-19 urgent public  
221 health study, funded by the Royal Devon and Exeter NHS Foundation Trust, Hull University Teaching  
222 Hospital NHS Trust, and by unrestricted educational grants from F. Hoffmann-La Roche AG  
223 (Switzerland), Biogen GmbH (Switzerland), Celltrion Healthcare (South Korea) and Galapagos NV  
224 (Belgium). None of our funding bodies had any role in study design, data collection or analysis,  
225 writing, or decision to submit for publication.

## 226 **Results**

227 Between September 22<sup>nd</sup> 2020 and December 23<sup>rd</sup> 2020, 7226 patients were recruited to the  
228 CLARITY study from 92 UK hospitals.<sup>11</sup> For the primary immunogenicity analyses we included 865  
229 infliximab- and 428 vedolizumab-treated participants without evidence of prior SARS-CoV-2  
230 infection, who had received uninterrupted biologic therapy since recruitment and had an antibody  
231 test between 21 and 70 days after primary vaccination. Participant characteristics are shown in Table  
232 1.

## Infliximab and immunomodulators reduce immunogenicity of a single-dose of SARS-CoV-2 vaccines

### 233 *Anti-SARS-CoV-2 (S) antibody level following primary COVID-19 vaccine*

234 Geometric mean [geometric SD] anti-SARS-CoV-2 (S) antibody concentrations were lower in patients  
235 treated with infliximab than vedolizumab, following both the BNT162b2 (6.0 U/mL [5.9] vs 28.8  
236 U/mL [5.4] P<0.0001) and ChAdOx1 nCoV-19 (4.7 U/mL [4.9] vs 13.8 U/mL [5.9] P<0.0001) vaccines  
237 (Figure 1). Amongst infliximab-treated patients, the geometric mean [geometric SD] anti-SARS-CoV-2  
238 (S) antibody concentrations were also lower in patients treated with a concomitant  
239 immunomodulator. Additional univariable analyses are shown in Table 2.

240

241 In our multivariable models, anti-SARS-CoV-2 antibody concentrations were lower in infliximab-  
242 compared with vedolizumab-treated patients in participants who received the BNT162b2 (fold  
243 change [FC] 0.29 [95% CI 0.21, 0.40], p<0.0001) and ChAdOx1 nCoV-19 [FC] 0.39 [95% CI 0.30, 0.51],  
244 p<0.0001) vaccines. Age  $\geq$  60 years, immunomodulator use, and current smoking were also  
245 independently associated with lower anti-SARS-CoV-2 antibody concentrations in participants who  
246 received either vaccine. Conversely, non-white ethnicity was associated with higher antibody  
247 concentrations following both vaccines (figure 2).

248

249 The 15-day rolling geometric mean of anti-SARS-CoV-2 antibody concentrations are shown in  
250 Figure 3. Three weeks after vaccination, we observed lower anti-SARS-CoV-2 (S) antibody  
251 concentrations in infliximab- compared to vedolizumab-treated patients following both vaccines.  
252 Sustained serological responses were observed in the vedolizumab- but not infliximab-treated  
253 patients.

254

255



## Infliximab and immunomodulators reduce immunogenicity of a single-dose of SARS-CoV-2 vaccines

### 256 *Seroconversion following primary COVID-19 vaccination*

257 The lowest rates of seroconversion were observed in participants treated with infliximab in  
258 combination with an immunomodulator with both the BNT162b2 (34.2%; 97/284) or ChAdOx1  
259 nCoV-19 (27.4%; 93/340) vaccines. Highest rates of seroconversion were seen in patients treated  
260 with vedolizumab monotherapy who received the BNT162b2 (77.2%;142/184) or ChAdOx1 nCoV-19  
261 (61.3%; 117/191) vaccines (Figure 4).

### 262 *Antibody responses following prior SARS-CoV-2 infection and two COVID-19 vaccine doses*

263 Amongst participants with SARS-CoV-2 infection prior to vaccination, geometric mean [SD] anti-  
264 SARS-CoV-2 (S) antibody concentrations were lower in infliximab- compared with vedolizumab-  
265 treated patients in those who received a single-dose of BNT162b2 (191 U/mL [12.5] vs 1865 U/mL  
266 [8.0]  $P < 0.0001$ ) and ChAdOx1 nCoV-19 (185 U/mL [9.3] vs 752 [12.5]  $P = 0.046$ ) vaccines. In both  
267 infliximab- and vedolizumab-treated patients, antibody concentrations following vaccination were  
268 higher than those observed in patients without prior infection (Figure 5). Overall, across both  
269 vaccines, 82% (76/93) patients treated with infliximab and 97% (33/34) patients treated with  
270 vedolizumab seroconverted ( $p = 0.041$ ).

271 Antibody responses were assessed in 27 patients following two doses of the BNT162b2 vaccine  
272 without serological evidence of prior infection (Figure 5). In both infliximab- and vedolizumab-  
273 treated patients, antibody levels and seroconversion rates were higher after two doses than after a  
274 primary vaccine without prior infection (geometric means infliximab 158 U/mL [7.0] vs 6.0 U/mL  
275 [5.9],  $p < 0.0001$ ; vedolizumab 562 U/mL [11.5] vs 28.8 U/mL [5.4],  $p = 0.018$ ). After second-vaccine  
276 doses 85% (17/20) infliximab- and 86% (6/7) vedolizumab-treated patients seroconverted ( $p = 0.68$ ).

277

## Infliximab and immunomodulators reduce immunogenicity of a single-dose of SARS-CoV-2 vaccines

### 278 **Discussion**

#### 279 ***Key results***

280 We have shown that anti-SARS-CoV-2 spike antibody levels and rates of seroconversion are lower  
281 following vaccination with a single-dose of either BNT162b2 or ChAdOx1 nCoV-19 vaccines in  
282 patients with IBD treated with infliximab than vedolizumab. Combination therapy with an  
283 immunomodulator further attenuated immunogenicity to both vaccines in infliximab-treated  
284 patients. Reassuringly, however, a second exposure to antigen, either by vaccination after infection,  
285 or a second dose of vaccine led to seroconversion in most patients.

286 Direct comparisons between our data and the antibody responses reported in the vaccine  
287 registration trials are limited by differences in the assays used to define immunogenicity and the  
288 adoption of different thresholds to define seroconversion. No adequately powered studies have  
289 reported the effect of anti-TNF drugs on vaccine responses.<sup>17</sup> Our findings are similar, however, to  
290 recent reports of the immunogenicity of the BNT162b2 and mRNA-1273 vaccines in transplant  
291 recipients and in patients with malignancy treated with anti-metabolite immunosuppression,  
292 conventional chemotherapy or immune checkpoint inhibitors.<sup>18,19</sup> The authors showed fewer  
293 patients treated with potent immunosuppressants seroconverted than healthy controls.  
294 Importantly, as we have also shown here, second vaccine doses led to seroconversion in the cancer  
295 cohort. However, even after two antigen exposures, a small subset of patients (18% [20/113]  
296 infliximab-treated patients and 5% [2/41] vedolizumab-treated patients) in our study failed to mount  
297 an antibody response. To identify this group, and because the sustainability of antibody responses  
298 overall is unknown, serial measurement of antibody responses are indicated.

299 Urgent research is needed to understand the factors linked to non-response and how to potentiate  
300 long-term immunogenicity in this group. Strategies to be tested include the manipulation of timing

## Infliximab and immunomodulators reduce immunogenicity of a single-dose of SARS-CoV-2 vaccines

301 of second vaccinations of second vaccinations, booster doses, the use of adjuvants and/or switching  
302 between vaccines with different mechanisms of action. Moreover, from the public health  
303 standpoint, recent case reports have shown that potent immunosuppression leads to chronic  
304 nasopharyngeal carriage and evolution of new SARS-CoV-2 variants.<sup>20,21</sup> Whether this occurs in  
305 patients treated with anti-TNF therapy with impaired antibody response is an important conceptual  
306 concern.

307 Our data has other important findings relating to SARS-CoV-2 vaccine responses. We have  
308 demonstrated that antibody responses to SARS-CoV-2 vaccines are reduced in older individuals and  
309 current smokers. Smoking has also been associated with lower antibody responses to hepatitis B  
310 vaccination and faster decay of antibodies after vaccination with live attenuated and trivalent  
311 influenza vaccines.<sup>22,23</sup> We have also demonstrated higher antibody responses to both the BNT162b2  
312 and ChAdOx1 nCoV-19 vaccines in non-white participants. This might be explained by differences in  
313 genetics,<sup>24</sup> gut microbiota,<sup>25</sup> nutrition,<sup>26</sup> and priming of the immune system by prior exposure to  
314 SARS-CoV-2 not detected by our pre-vaccination antibody test. Lower antibody concentrations were  
315 also observed in patients with Crohn's disease when compared to patients with ulcerative colitis or  
316 IBD-unclassified. Despite evidence of defective mucosal immunity, previous vaccine studies involving  
317 patients with Crohn's disease or ulcerative colitis have not shown attenuated antibody responses to  
318 vaccination in the absence of concomitant immunomodulator or biologic therapy.<sup>6,7</sup>

319 The cytokine TNF shapes multiple aspects of host immune responses, including T-cell dependent  
320 antibody production. Genetic ablation of TNF results in disruption of B-cell follicles in germinal  
321 centres with defective induction of antigen-induced antibody production.<sup>27,28</sup> These biological  
322 properties may in part explain why TNF blockade is clinically beneficial in IMiDs, but also explain the  
323 increased risk of serious and opportunistic infections and impaired response to other vaccines.

## Infliximab and immunomodulators reduce immunogenicity of a single-dose of SARS-CoV-2 vaccines

324 Whilst our data are biologically plausible, we acknowledge the following limitations of our study. We  
325 have used an electrochemiluminescence immunoassay to measure antibody concentrations rather  
326 than using a neutralising assay. Although neutralisation assays are considered more biologically  
327 relevant, it is now established that anti receptor-binding domain antibodies, which target the spike  
328 protein component that engages host cells through ligation of angiotensin-converting enzyme 2,  
329 closely correlate with neutralisation assays.<sup>29,30</sup> Second, we only assessed humoral responses to  
330 infection, and it is likely that protective immunity additionally requires induction of memory T cell  
331 responses. Finally, we investigated one anti-TNF drug, infliximab, only. However, we suspect that our  
332 key findings will apply to other anti-TNF biologics used to treat IMIDs, including adalimumab,  
333 certolizumab, golimumab, and etanercept. Further observational data will be required to elucidate  
334 the impact of other classes of therapies for IMIDs on SARS-CoV-2 vaccine immunogenicity.

335 Our findings have important implications for patients treated with anti-TNF drugs particularly those  
336 also treated with an immunomodulator. Poor antibody responses to a single-dose of vaccine  
337 unnecessarily exposes infliximab-treated patients to SARS-CoV-2 infection. However, because we  
338 observed higher rates of seroconversion in patients with two exposures to SARS-CoV-2 antigen, even  
339 in the presence of TNF blockade, these patients should be prioritised for optimally timed second  
340 doses. Until patients receive a second dose of vaccine they should consider that they are not  
341 protected from SARS-CoV-2 infection and continue to practice enhanced physical distancing and  
342 shielding if appropriate.

## 343 **Conclusion**

344 Infliximab is associated with attenuated immunogenicity to a single-dose of the BNT162b2 and  
345 ChAdOx1 nCoV-19 SARS-CoV-2 vaccines in patients with inflammatory bowel disease.  
346 Immunomodulators further blunted immunogenicity rates to both vaccines. Reassuringly,

## Infliximab and immunomodulators reduce immunogenicity of a single-dose of SARS-CoV-2 vaccines

347 vaccination after infection, or a second dose of vaccine led to seroconversion in most patients.

348 Delayed second dosing should be avoided in patients treated with infliximab.

349

350

Infliximab and immunomodulators reduce immunogenicity of a single-dose of SARS-CoV-2 vaccines

351 **Table 1: Baseline characteristics of participants who had anti-SARS-CoV-2 spike antibodies**  
352 **measured 3 to 10 weeks following primary vaccination against SARS-CoV-2**

Variable		Infliximab	Vedolizumab	Overall	p
Vaccine	BNT162b2	44.7% (387/865)	47.2% (202/428)	45.6% (589/1293)	0.41
	ChAdOx1 nCoV-19	55.3% (478/865)	52.8% (226/428)	54.4% (704/1293)	
Age (years)		41.4 (31.5 - 54.8)	49.6 (37.1 - 63.8)	43.8 (32.8 - 57.6)	<0.0001
Sex	Female	50.3% (434/863)	47.1% (200/425)	49.2% (634/1288)	0.19
	Male	49.7% (429/863)	52.7% (224/425)	50.7% (653/1288)	
	Intersex	0.0% (0/863)	0.0% (0/425)	0.0% (0/1288)	
	Prefer not to say	0.0% (0/863)	0.2% (1/425)	0.1% (1/1288)	
Ethnicity	White	91.8% (791/862)	89.9% (381/424)	91.1% (1172/1286)	0.62
	Asian	5.3% (46/862)	7.5% (32/424)	6.1% (78/1286)	
	Mixed	1.9% (16/862)	1.9% (8/424)	1.9% (24/1286)	
	Black	0.7% (6/862)	0.5% (2/424)	0.6% (8/1286)	
	Other	0.3% (3/862)	0.2% (1/424)	0.3% (4/1286)	
Diagnosis	Crohn's disease	65.4% (566/865)	40.7% (174/428)	57.2% (740/1293)	0.00050
	Ulcerative colitis or IBD-unclassified	34.6% (299/865)	59.3% (254/428)	42.8% (553/1293)	
Duration of IBD (years)		8.0 (4.0 - 16.0)	10.0 (5.0 - 17.8)	9.0 (4.0 - 16.0)	0.0040
Age at IBD diagnosis (years)		28.8 (21.6 - 41.8)	34.0 (23.3 - 47.6)	30.3 (21.9 - 43.7)	<0.0001
Immunomodulator		61.6% (533/865)	22.0% (94/427)	48.5% (627/1292)	<0.0001
5-ASA		23.0% (199/865)	31.6% (135/427)	25.9% (334/1292)	0.0012
Steroids		3.0% (26/865)	8.4% (36/427)	4.8% (62/1292)	<0.0001
BMI (kg/m <sup>2</sup> )		25.9 (22.8 - 30.6)	26.1 (23.1 - 30.1)	26.0 (22.9 - 30.4)	0.75
Heart disease		3.6% (31/865)	6.5% (28/428)	4.6% (59/1293)	0.023
Diabetes		3.8% (33/865)	7.5% (32/428)	5.0% (65/1293)	0.0065
Lung disease		13.5% (117/865)	18.2% (78/428)	15.1% (195/1293)	0.032
Kidney disease		1.2% (10/865)	2.1% (9/428)	1.5% (19/1293)	0.22
Cancer		0.5% (4/865)	2.1% (9/428)	1.0% (13/1293)	0.013
Smoker	Yes	9.7% (84/862)	5.4% (23/425)	8.3% (107/1287)	0.0010
	Not currently	32.0% (276/862)	41.6% (177/425)	35.2% (453/1287)	
	Never	58.2% (502/862)	52.9% (225/425)	56.5% (727/1287)	
Exposure to documented cases of COVID-19		9.4% (81/862)	8.7% (37/425)	9.2% (118/1287)	0.76
Income deprivation score		0.086 (0.052 - 0.151)	0.084 (0.054 - 0.141)	0.086 (0.052 - 0.147)	0.94
Active disease (PRO2)		4.9% (41/831)	11.4% (46/405)	7.0% (87/1236)	<0.0001

353  
354 **Abbreviations:** IBD = inflammatory bowel disease; 5-ASA = 5-aminosalicylic acid; BMI = Body Mass  
355 Index; PRO2 = IBD disease activity. Values presented are median (interquartile range) or percentage  
356 (numerator/denominator). P values represent the results of a Mann Whitney U, Kruskal Wallis or  
357 Fisher's exact test.

Infliximab and immunomodulators reduce immunogenicity of a single-dose of SARS-CoV-2 vaccines

358 **Table 2: Univariable associations with anti-SARS-CoV-2 spike antibodies, stratified by**  
 359 **vaccine type**

Variable		BNT162b2		ChAdOx1 nCoV-19	
		Value	p	Value	p
Biologic treatment	Infliximab	6.0 (5.9)	<0.0001	4.7 (4.9)	<0.0001
	Vedolizumab	28.8 (5.4)		13.8 (5.9)	
Immunomodulator in infliximab-treated participants	No	9.7 (4.7)	<0.0001	5.7 (5.1)	0.045
	Yes	4.4 (6.3)		4.2 (4.7)	
Immunomodulator in vedolizumab-treated participants	No	32.4 (5.2)	0.052	15.6 (6.0)	0.082
	Yes	16.7 (6.3)		10.0 (5.5)	
Age (years)		rho = -0.22	<0.0001	rho = -0.15	<0.0001
Sex	Female	9.4 (7.0)	0.092	6.6 (5.5)	0.83
	Male	10.9 (6.3)		6.8 (5.7)	
Ethnicity	White	9.4 (6.6)	0.037	6.2 (5.6)	0.0051
	Asian	20.9 (7.3)		16.1 (5.2)	
	Mixed	25.7 (6.7)		13.7 (5.3)	
	Black	12.5 (1.6)		19.4 (2.2)	
	Other	22.9 (3.7)		5.7 (3.1)	
Diagnosis	Crohn's disease	7.3 (6.4)	<0.0001	5.6 (5.6)	0.0014
	Ulcerative colitis or IBD-unclassified	15.6 (6.5)		8.5 (5.5)	
Duration of IBD (years)		rho = -0.16	<0.0001	rho = -0.12	0.0013
Age at IBD diagnosis (years)		rho = -0.13	0.0021	rho = -0.04	0.25
5-ASA	No	9.8 (6.6)	0.40	6.7 (5.5)	0.93
	Yes	11.5 (7.1)		6.6 (5.9)	
Steroids	No	10.2 (6.7)	0.90	6.8 (5.5)	0.12
	Yes	10.7 (7.3)		4.1 (6.7)	
BMI (kg/m <sup>2</sup> )		rho = -0.08	0.068	rho = -0.01	0.81
Heart disease	No	10.3 (6.7)	0.65	6.9 (5.6)	0.010
	Yes	8.7 (7.0)		2.8 (5.2)	
Diabetes	No	10.7 (6.7)	0.0028	6.8 (5.6)	0.066
	Yes	4.1 (4.6)		4.0 (5.2)	
Lung disease	No	10.1 (6.9)	0.70	6.9 (5.5)	0.31
	Yes	10.9 (5.7)		5.7 (6.1)	
Kidney disease	No	10.2 (6.6)	0.60	6.7 (5.5)	0.66
	Yes	15.6 (10.4)		4.7 (12.4)	
Cancer	No	10.4 (6.6)	0.13	6.7 (5.6)	0.069
	Yes	2.0 (9.2)		2.3 (3.6)	
Smoking	Yes	4.7 (7.1)	0.0077	3.4 (4.8)	0.00077
	Not currently	9.4 (6.6)		6.1 (5.4)	
	Never	11.8 (6.5)		8.0 (5.7)	
Exposure to documented cases of COVID-19	No	10.3 (6.7)	0.87	6.6 (5.5)	0.53
	Yes	9.8 (6.8)		7.8 (6.1)	
Income deprivation score		rho = 0.01	0.75	rho = 0.02	0.65
Active disease (PRO2)	No	10.1 (6.5)	0.32	6.6 (5.4)	0.51
	Yes	14.0 (7.6)		8.1 (7.0)	

360 **Abbreviations:** IBD = inflammatory bowel disease; 5-ASA = 5-aminosalicylic acid; VAS = visual  
 361 analogue scale. Values presented are geometric mean antibody concentration (geometric standard  
 362 deviation) or Spearman's rho. P values represent the results of an unpaired t test or test of  
 363 Spearman's rho.

## Infliximab and immunomodulators reduce immunogenicity of a single-dose of SARS-CoV-2 vaccines

### 364 **Figure Captions**

365 **Figure 1:** Anti-SARS-CoV-2 spike antibody concentration stratified by biologic therapy (infliximab vs  
366 vedolizumab) and type of vaccine. The wider bar represents the geometric mean, while the narrower  
367 bars are drawn one geometric standard deviation either side of the geometric mean. The threshold  
368 shown of 15 U/mL is the one used to determine seroconversion.

369 **Figure 2:** Exponentiated coefficients of linear regression models of log(anti-SARS-CoV-2 spike  
370 antibody concentration). The resultant values represent the fold change of antibody concentration  
371 associated with each variable. Each vaccine was modelled separately, and then a further model was  
372 created using all of the available data.

373 **Figure 3:** Rolling geometric mean antibody concentration over time stratified by biologic therapy  
374 (infliximab vs vedolizumab) and vaccine. Geometric means are calculated using a rolling 15 day  
375 window (i.e. 7 days either side of the day indicated). The shaded areas represent the 95% confidence  
376 intervals of the geometric means. Overall, data from 2126 participants (1427 on infliximab and 699  
377 on vedolizumab) are included in this graph between 1 and 63 days post vaccination.

378 **Figure 4:** Percentages of participants with seroconversion defined by an anti-SARS-CoV-2 spike  
379 antibody concentration  $\geq 15$  U/mL, stratified by vaccine, biologic and immunomodulator use. Error  
380 bars represent the 95% confidence interval of the percentages. **Abbreviations:** IMM =  
381 immunomodulator

382 **Figure 5:** Anti-SARS-CoV-2 spike antibody concentration stratified by biologic therapy (infliximab vs  
383 vedolizumab), prior infection, number of doses and type of vaccine. The wider bar represents the  
384 geometric mean, while the narrower bars are drawn one geometric standard deviation either side of  
385 the geometric mean. The threshold shown of 15 U/mL is the one used to determine seroconversion.



## Infliximab and immunomodulators reduce immunogenicity of a single-dose of SARS-CoV-2 vaccines

### 386 **Contributions**

387 NAK, JRG, CB, SS, NP, TA participated in the conception and design of this study. CB was the project  
388 manager and coordinated patient recruitment. RN and TJM coordinated all biochemical analyses and  
389 central laboratory aspects of the project. NAK, SL, JRG, NC, BH, DC, JRF, AF, PMI, NK, KBK, CAL, JM,  
390 SJM, RCGP, TR, PJS, AMV, TJM, SS, CWL, NP, TA were involved in the acquisition, analysis, or  
391 interpretation of data. Data analysis was done by NAK. Drafting of the manuscript was done by NAK,  
392 SL, JRG, NC, RN, DC, RCGP, SS, CWL, NP, TA. SS, NP and TA obtained the funding for the study. All the  
393 authors contributed to the critical review and final approval of the manuscript. NAK and TA have  
394 verified the underlying data.

### 395 **Declarations of interest**

396 Dr. Kennedy reports grants from F. Hoffmann-La Roche AG, grants from Biogen Inc, grants from  
397 Celltrion Healthcare, grants from Galapagos NV, non-financial support from Immundiagnostik, during  
398 the conduct of the study; grants and non-financial support from AbbVie, grants and personal fees  
399 from Celltrion, personal fees and non-financial support from Janssen, personal fees from Takeda,  
400 personal fees and non-financial support from Dr Falk, outside the submitted work. Dr. Lin reports  
401 non-financial support from Pfizer, non-financial support from Ferring, outside the submitted work.  
402 Dr. Goodhand reports grants from F. Hoffmann-La Roche AG, grants from Biogen Inc, grants from  
403 Celltrion Healthcare, grants from Galapagos NV, non-financial support from Immundiagnostik, during  
404 the conduct of the study. Dr. Chee reports non-financial support from Ferring, personal fees and  
405 non-financial support from Pfizer, outside the submitted work. Dr. Cummings reports grants and  
406 personal fees from Samsung, Pfizer & Biogen; personal fees and non-financial support from Janssen  
407 & Abbvie; grants, personal fees and non-financial support from Takeda; personal fees from MSD,  
408 Sandoz, Celltrion & NAPP, outside the submitted work. Dr. Irving reports grants and personal fees  
409 from Takeda, grants from MSD, grants and personal fees from Pfizer, personal fees from Galapagos,

## Infliximab and immunomodulators reduce immunogenicity of a single-dose of SARS-CoV-2 vaccines

410 personal fees from Gilead, personal fees from Abbvie, personal fees from Janssen, personal fees  
411 from Boehringer Ingelheim, personal fees from Topivert, personal fees from VH2, personal fees from  
412 Celgene, personal fees from Arena, personal fees from Samsung Bioepis, personal fees from Sandoz,  
413 personal fees from Procise, personal fees from Prometheus, outside the submitted work. Dr.  
414 Kamperidis reports personal fees from Janssen, outside the submitted work. Dr. Kok reports  
415 personal fees from Janssen, personal fees from Takeda, personal fees from PredictImmune, personal  
416 fees from Amgen, outside the submitted work. Dr. Lamb reports grants from Genentech, grants and  
417 personal fees from Janssen, grants and personal fees from Takeda, grants from AbbVie, personal  
418 fees from Ferring, grants from Eli Lilly, grants from Pfizer, grants from Roche, grants from UCB  
419 Biopharma, grants from Sanofi Aventis, grants from Biogen IDEC, grants from Orion OYJ, personal  
420 fees from Dr Falk Pharma, grants from AstraZeneca, outside the submitted work. Dr. Macdonald  
421 reports grants and personal fees from Takeda Pharmaceuticals, grants and personal fees from  
422 Biogen, personal fees and non-financial support from AbbVie, personal fees from Grifols, personal  
423 fees from Sandoz, personal fees from Celltrion, personal fees and non-financial support from  
424 Janssen, personal fees from Vifor Pharmaceuticals, personal fees from Predictimmune, personal fees  
425 from Bristol Myers Squibb, non-financial support from Ferring Pharmaceuticals, outside the  
426 submitted work. Prof. Pollok reports acting as consultant, advisory board member, speaker or  
427 recipient of educational grant from Dr Falk, Ferring, Janssen, Pharmacosmos and Takeda. Dr. Raine  
428 reports grants and personal fees from Abbvie, personal fees from BMS, personal fees from Celgene,  
429 personal fees from Ferring, personal fees from Gilead, personal fees from GSK, personal fees from  
430 LabGenius, personal fees from Janssen, personal fees from Mylan, personal fees from MSD, personal  
431 fees from Novartis, personal fees from Pfizer, personal fees from Sandoz, personal fees from Takeda,  
432 personal fees from Galapagos, personal fees from Arena, outside the submitted work. Dr Smith  
433 reports speaker fees and advisory board sponsorship from Janssen, Celltrion and Takeda outside the  
434 submitted work. Dr. Verma reports personal fees and non-financial support from Takeda, personal

## Infliximab and immunomodulators reduce immunogenicity of a single-dose of SARS-CoV-2 vaccines

435 fees and non-financial support from Celltrion, personal fees and non-financial support from Merck  
436 Sharp & Dohme, outside the submitted work. Prof. Sebastian reports grants from Takeda, Abbvie,  
437 AMGEN, Tillots Pharma, personal fees from Jaansen, Takeda, Galapagos, Celltrion, Falk Pharma,  
438 Tillots pharma, Cellgene, Pfizer, Pharmacocosmos, outside the submitted work. Prof. Lees reports  
439 personal fees from Abbvie, personal fees from Janssen, personal fees from Pfizer, personal fees from  
440 Takeda, grants from Gilead, personal fees from Gilead, personal fees from Galapagos, personal fees  
441 from Iterative Scopes, personal fees from Trellus Health, personal fees from Celltion, personal fees  
442 from Ferring, personal fees from BMS, during the conduct of the study. Dr. Powell reports personal  
443 fees from Takeda, personal fees from Janssen, personal fees from Pfizer, personal fees from Bristol-  
444 Myers Squibb, personal fees from Abbvie, personal fees from Roche, personal fees from Lilly,  
445 personal fees from Allergan, personal fees from Celgene, outside the submitted work; and Dr. Powell  
446 has served as a speaker/advisory board member for Abbvie, Allergan, Bristol Myers Squibb, Celgene,  
447 Falk, Ferring, Janssen, Pfizer, Tillotts, Takeda and Vifor Pharma. Prof. Ahmad reports grants and non-  
448 financial support from F. Hoffmann-La Roche AG, grants from Biogen Inc, grants from Celltrion  
449 Healthcare, grants from Galapagos NV, non-financial support from Immundiagnostik, during the  
450 conduct of the study; personal fees from Biogen inc, grants and personal fees from Celltrion  
451 Healthcare, personal fees and non-financial support from Immundiagnostik, personal fees from  
452 Takeda, personal fees from ARENA, personal fees from Gilead, personal fees from Adcock Ingram  
453 Healthcare, personal fees from Pfizer, personal fees from Genentech, non-financial support from  
454 Tillotts, outside the submitted work. The following authors have nothing to declare: Neil Chanchlani,  
455 Ben Hamilton, Claire Bewshea, Rachel Nice, Shameer J Mehta, Timothy J McDonald.

456

## Infliximab and immunomodulators reduce immunogenicity of a single-dose of SARS-CoV-2 vaccines

### 457 **Acknowledgements**

458 CLARITY IBD is a UK National Institute for Health Research (NIHR) Urgent Public Health Study. The  
459 NIHR Clinical Research Network supported study set-up, site identification, and delivery of this study.  
460 This was facilitated by Professor Mark Hull, the National speciality lead for Gastroenterology. We  
461 acknowledge the contribution of our Patient Advisory Group who helped shape the trial design  
462 around patient priorities. Our partners, Crohn's and Colitis UK (CCUK), continue to support this  
463 group and participate in Study Management Team meetings. We thank Professor Danny Altmann,  
464 Professor Rosemary Boyton, Professor Graham Cooke and Dr Katrina Pollock for their helpful  
465 discussions and review of the data. Laboratory tests were undertaken by the Exeter Blood Sciences  
466 Laboratory at the Royal Devon and Exeter NHS Foundation Trust. The Exeter NIHR Clinical Research  
467 Facility coordinated sample storage and management. Tariq Malik and James Thomas from Public  
468 Health England, Guy Stevens, Katie Donelon, Elen de Lacy from Public Health Wales and Johanna  
469 Bruce from Public Health Scotland supported linkage of central SARS-CoV-2 PCR test results with  
470 study data. Roche Diagnostics Limited provided the Elecsys Anti-SARS-CoV-2 immunoassay for the  
471 study. SL is supported by a Wellcome GW4-CAT fellowship. NC acknowledges support from CCUK.  
472 CAL acknowledges support from the NIHR Newcastle Biomedical Research Centre and the support of  
473 the Programmed Investigation Unit at Royal Victoria Infirmary, Newcastle upon Tyne. TR  
474 acknowledges support with recruitment from the NIHR Cambridge BRC. CWL is funded by a UKRI  
475 Future Leaders Fellowship. NP is supported by the NIHR Imperial Biomedical Research Center (BRC).  
476 We acknowledge the study co-ordinators of the Exeter Inflammatory Bowel Disease Research Group:  
477 Marian Parkinson and Helen Gardner-Thorpe for their ongoing administrative support to the study.  
478 The sponsor of the study was the Royal Devon and Exeter NHS Foundation Trust.

## Infliximab and immunomodulators reduce immunogenicity of a single-dose of SARS-CoV-2 vaccines

### 479 **Patient involvement**

480 We conducted an electronic survey to gauge the opinion of patients with IBD on the patient  
481 questionnaires to be delivered as part of the CLARITY IBD study. We surveyed 250 patients across 74  
482 hospitals. All our proposed questions for study inclusion were rated as important or very important  
483 by at least 83% of participants. The Exeter IBD Patient Panel refined the questions included in the  
484 study questionnaire, reviewed the study protocol, supported the writing of the patient information  
485 sheets, and participated in testing of the electronic consent form and patient questionnaire. A  
486 member of the Exeter IBD Patient Panel sits on the study management committee, ensuring patient  
487 involvement in all aspects of study delivery, data analysis and dissemination of findings.

### 488 **Data sharing**

489 The study protocol including the statistical analysis plan is available at [www.clarityibd.org](http://www.clarityibd.org). Individual  
490 participant de-identified data that underlie the results reported in this article will be available  
491 immediately after publication for a period of 5 years. The data will be made available to investigators  
492 whose proposed use of the data has been approved by an independent review committee. Analyses  
493 will be restricted to the aims in the approved proposal. Proposals should be directed to  
494 [tariq.ahmad1@nhs.net](mailto:tariq.ahmad1@nhs.net). To gain access data requestors will need to sign a data access agreement.

495


496

## 497 References

- 498 1 Joint Committee on Vaccination and Immunisation. Optimising the COVID-19 vaccination  
499 programme for maximum short-term impact. 2021.  
500 [https://www.gov.uk/government/publications/prioritising-the-first-covid-19-vaccine-dose-](https://www.gov.uk/government/publications/prioritising-the-first-covid-19-vaccine-dose-jcvi-statement/optimising-the-covid-19-vaccination-programme-for-maximum-short-term-impact)  
501 [jcvi-statement/optimising-the-covid-19-vaccination-programme-for-maximum-short-term-](https://www.gov.uk/government/publications/prioritising-the-first-covid-19-vaccine-dose-jcvi-statement/optimising-the-covid-19-vaccination-programme-for-maximum-short-term-impact)  
502 [impact](https://www.gov.uk/government/publications/prioritising-the-first-covid-19-vaccine-dose-jcvi-statement/optimising-the-covid-19-vaccination-programme-for-maximum-short-term-impact) (accessed March 20, 2021).
- 503 2 European Centre for Disease Prevention and Control. Overview of the implementation of  
504 COVID-19 vaccination strategies and vaccine deployment plans in the EU/EEA. 2021.
- 505 3 National Advisory Committee on Immunization. COVID-19 vaccine extended dose interval for  
506 Canadians. 2021. [https://www.canada.ca/en/public-health/services/immunization/national-](https://www.canada.ca/en/public-health/services/immunization/national-advisory-committee-on-immunization-naci/rapid-response-extended-dose-intervals-covid-19-vaccines-early-rollout-population-protection.html)  
507 [advisory-committee-on-immunization-naci/rapid-response-extended-dose-intervals-covid-](https://www.canada.ca/en/public-health/services/immunization/national-advisory-committee-on-immunization-naci/rapid-response-extended-dose-intervals-covid-19-vaccines-early-rollout-population-protection.html)  
508 [19-vaccines-early-rollout-population-protection.html](https://www.canada.ca/en/public-health/services/immunization/national-advisory-committee-on-immunization-naci/rapid-response-extended-dose-intervals-covid-19-vaccines-early-rollout-population-protection.html) (accessed March 22, 2021).
- 509 4 Jones GR, Lyons M, Plevris N, *et al.* IBD prevalence in Lothian, Scotland, derived by capture-  
510 recapture methodology. *Gut* 2019; **68**: 1953–60.
- 511 5 Hamilton B, Green H, Heerasing N, *et al.* Incidence and prevalence of inflammatory bowel  
512 disease in Devon, UK. *Frontline Gastroenterol* 2020; published online June 24.  
513 DOI:10.1136/flgastro-2019-101369.
- 514 6 Melmed GY, Agarwal N, Frenck RW, *et al.* Immunosuppression Impairs Response to  
515 Pneumococcal Polysaccharide Vaccination in Patients With Inflammatory Bowel Disease. *Am J*  
516 *Gastroenterol* 2010; **105**: 148–54.
- 517 7 Caldera F, Hillman L, Saha S, *et al.* Immunogenicity of High Dose Influenza Vaccine for Patients  
518 with Inflammatory Bowel Disease on Anti-TNF Monotherapy: A Randomized Clinical Trial.  
519 *Inflamm Bowel Dis* 2019; **26**: 593–602.
- 520 8 Pratt PK, David N, Weber HC, *et al.* Antibody Response to Hepatitis B Virus Vaccine is  
521 Impaired in Patients with Inflammatory Bowel Disease on Infliximab Therapy. *Inflamm Bowel*  
522 *Dis* 2018; **24**: 380–6.
- 523 9 Long MD, Martin C, Sandler RS, Kappelman MD. Increased risk of pneumonia among patients  
524 with inflammatory bowel disease. *Am J Gastroenterol* 2013; **108**: 240–8.
- 525 10 Harrington JE, Hamilton RE, Ganley-Leal L, Farraye FA, Wasan SK. The Immunogenicity of the  
526 Influenza, Pneumococcal, and Hepatitis B Vaccines in Patients With Inflammatory Bowel  
527 Disease Treated With Vedolizumab. *Crohn's Colitis 360* 2020; **2**. DOI:10.1093/crocol/otaa082.
- 528 11 Kennedy NA, Goodhand JR, Bewshea C, *et al.* Inflammatory bowel disease Anti-SARS-CoV-2  
529 antibody responses are attenuated in patients with IBD treated with infliximab. *Gut* 2021; **0**:  
530 1–11.
- 531 12 Harris PA, Taylor R, Minor BL, *et al.* The REDCap consortium: Building an international  
532 community of software platform partners. *J. Biomed. Inform.* 2019; **95**.  
533 DOI:10.1016/j.jbi.2019.103208.
- 534 13 Roche Diagnostics GmbH. Elecsys® Anti-SARS-CoV-2 S assay method sheet. 2020.  
535 <https://diagnostics.roche.com/gb/en/products/params/electsys-anti-sars-cov-2-s.html>  
536 (accessed March 24, 2021).
- 537 14 Muench P, Jochum S, Wenderoth V, *et al.* Development and validation of the elecsys anti-  
538 SARS-CoV-2 immunoassay as a highly specific tool for determining past exposure to SARS-  
539 CoV-2. *J Clin Microbiol* 2020; **58**: 1694–714.
- 540 15 Rubio-Acero R, Castelletti N, Fingerle V, *et al.* In search for the SARS-CoV-2 protection  
541 correlate: A head-to-head comparison of two quantitative S1 assays in a group of pre-  
542 characterized oligo-/asymptomatic patients. *medRxiv* 2021; : 2021.02.19.21252080.
- 543 16 L'Huillier AG, Meyer B, Andrey DO, *et al.* Antibody persistence in the first 6 months following  
544 SARS-CoV-2 infection among hospital workers: a prospective longitudinal study. *Clin*

## Infliximab and immunomodulators reduce immunogenicity of a single-dose of SARS-CoV-2 vaccines

- 545 *Microbiol Infect* 2021; **0**. DOI:10.1016/j.cmi.2021.01.005.
- 546 17 Alexander JL, Moran GW, Gaya DR, *et al*. SARS-CoV-2 vaccination for patients with  
547 inflammatory bowel disease: a British Society of Gastroenterology Inflammatory Bowel  
548 Disease section and IBD Clinical Research Group position statement. *Lancet Gastroenterol*  
549 *Hepatol* 2021; **6**: 218–24.
- 550 18 Boyarsky BJ, Werbel WA, Avery RK, *et al*. Immunogenicity of a Single Dose of SARS-CoV-2  
551 Messenger RNA Vaccine in Solid Organ Transplant Recipients. *JAMA* 2021; published online  
552 March 15. DOI:10.1001/jama.2021.4385.
- 553 19 Monin-Aldama L, Laing AG, McKenzie DR, *et al*. Interim results of the safety and immune-  
554 efficacy of 1 versus 2 doses of COVID-19 vaccine BNT162b2 for cancer patients in the context  
555 of the UK vaccine priority guidelines. *medRxiv* 2021; : 2021.03.17.21253131.
- 556 20 Choi B, Choudhary MC, Regan J, *et al*. Persistence and Evolution of SARS-CoV-2 in an  
557 Immunocompromised Host. *N Engl J Med* 2020; **383**: 2291–3.
- 558 21 Avanzato VA, Matson MJ, Seifert SN, *et al*. Case Study: Prolonged Infectious SARS-CoV-2  
559 Shedding from an Asymptomatic Immunocompromised Individual with Cancer. *Cell* 2020;  
560 **183**: 1901-1912.e9.
- 561 22 Winter AP, Follett EAC, McIntyre J, Stewart J, Symington IS. Influence of smoking on  
562 immunological responses to hepatitis B vaccine. *Vaccine* 1994; **12**: 771–2.
- 563 23 MacKenzie JS, MacKenzie IH, Holt PG. The effect of cigarette smoking on susceptibility to  
564 epidemic influenza and on serological responses to live attenuated and killed subunit  
565 influenza vaccines. *J Hyg (Lond)* 1976; **77**: 409–17.
- 566 24 Haralambieva IH, Ovsyannikova IG, Umlauf BJ, *et al*. Genetic polymorphisms in host antiviral  
567 genes: Associations with humoral and cellular immunity to measles vaccine. *Vaccine* 2011;  
568 **29**: 8988–97.
- 569 25 Huda MN, Lewis Z, Kalanetra KM, *et al*. Stool microbiota and vaccine responses of infants.  
570 *Pediatrics* 2014; **134**: e362–72.
- 571 26 Savy M, Edmond K, Fine PEM, *et al*. Landscape analysis of interactions between nutrition and  
572 vaccine responses in children. *J Nutr* 2009; **139**. DOI:10.3945/jn.109.105312.
- 573 27 Pasparakis M, Alexopoulou L, Episkopou V, Kollias G. Immune and inflammatory responses in  
574 TNF $\alpha$ -deficient mice: A critical requirement for TNF $\alpha$  in the formation of primary B cell  
575 follicles, follicular dendritic cell networks and germinal centers, and in the maturation of the  
576 humoral immune response. *J Exp Med* 1996; **184**: 1397–411.
- 577 28 Ritter U, Meissner A, Ott J, Körner H. Analysis of the maturation process of dendritic cells  
578 deficient for TNF and lymphotoxin- $\alpha$  reveals an essential role for TNF. *J Leukoc Biol* 2003; **74**:  
579 216–22.
- 580 29 Marot S, Malet I, Leducq V, *et al*. Rapid decline of neutralizing antibodies against SARS-CoV-2  
581 among infected healthcare workers. *Nat Commun* 2021; **12**: 1–7.
- 582 30 Edara VV, Hudson WH, Xie X, Ahmed R, Suthar MS. Neutralizing Antibodies Against SARS-CoV-  
583 2 Variants After Infection and Vaccination. *JAMA* 2021; published online March 19.  
584 DOI:10.1001/jama.2021.4388.
- 585  
586  
587





**BNT162b2**


Variable	N		Fold change (95% CI)	p
Infliximab (vs vedolizumab)	386/587		0.29 (0.21, 0.40)	<0.0001
Immunomodulator	269/587		0.41 (0.31, 0.55)	<0.0001
Crohn's disease (vs UC or IBDU)	327/587		0.75 (0.57, 1.00)	0.046
Age ≥ 60	113/587		0.34 (0.24, 0.47)	<0.0001
Non-white ethnicity	61/587		1.81 (1.16, 2.81)	0.0085
Current smoker	44/587		0.52 (0.31, 0.86)	0.011

**ChAdOx1 nCoV-19**

Variable	N		Fold change (95% CI)	p
Infliximab (vs vedolizumab)	475/697		0.39 (0.30, 0.51)	<0.0001
Immunomodulator	355/697		0.65 (0.50, 0.84)	0.00085
Crohn's disease (vs UC or IBDU)	409/697		0.85 (0.66, 1.09)	0.20
Age ≥ 60	162/697		0.48 (0.36, 0.65)	<0.0001
Non-white ethnicity	55/697		2.04 (1.31, 3.17)	0.0017
Current smoker	63/697		0.55 (0.36, 0.84)	0.0059

**All**

Variable	N		Fold change (95% CI)	p
Infliximab (vs vedolizumab)	861/1284		0.34 (0.27, 0.41)	<0.0001
Immunomodulator	624/1284		0.51 (0.42, 0.62)	<0.0001
Crohn's disease (vs UC or IBDU)	736/1284		0.79 (0.66, 0.96)	0.015
Age ≥ 60	275/1284		0.40 (0.32, 0.50)	<0.0001
Non-white ethnicity	116/1284		1.95 (1.43, 2.67)	<0.0001
Current smoker	107/1284		0.53 (0.39, 0.74)	0.00016



## BNT162b2

## ChAdOx1 nCoV-19

Percent seropositive

100%  
75%  
50%  
25%  
0%Infliximab  
with IMMInfliximab  
without IMMVedolizumab  
with IMMVedolizumab  
without IMMInfliximab  
with IMMInfliximab  
without IMMVedolizumab  
with IMMVedolizumab  
without IMM34.2%  
97/28442.8%  
77/18059.0%  
23/3977.2%  
142/18427.4%  
93/34031.7%  
64/20245.6%  
31/6861.3%  
117/191